233 related articles for article (PubMed ID: 7542336)
1. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh SL; Preston KL; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
7. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
Walsh SL; Sullivan JT; Preston KL; Garner JE; Bigelow GE
J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.
Lintzeris N; Mitchell TB; Bond AJ; Nestor L; Strang J
Drug Alcohol Depend; 2007 Dec; 91(2-3):187-94. PubMed ID: 17624687
[TBL] [Abstract][Full Text] [Related]
10. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
[TBL] [Abstract][Full Text] [Related]
11. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
12. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
Jones HE; Bigelow GE; Preston KL
J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
[TBL] [Abstract][Full Text] [Related]
13. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
Preston KL; Bigelow GE; Liebson IA
J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
[TBL] [Abstract][Full Text] [Related]
14. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.
Teoh SK; Mendelson JH; Mello NK; Kuehnle J; Sintavanarong P; Rhoades EM
J Clin Psychopharmacol; 1993 Apr; 13(2):87-99. PubMed ID: 8463453
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
16. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
Foltin RW; Fischman MW
J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
[TBL] [Abstract][Full Text] [Related]
17. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.
Lintzeris N; Mitchell TB; Bond A; Nestor L; Strang J
J Clin Psychopharmacol; 2006 Jun; 26(3):274-83. PubMed ID: 16702892
[TBL] [Abstract][Full Text] [Related]
18. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
[TBL] [Abstract][Full Text] [Related]
19. Drug discrimination in human postaddicts: agonist-antagonist opioids.
Preston KL; Bigelow GE; Bickel WK; Liebson IA
J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
[TBL] [Abstract][Full Text] [Related]
20. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]